AstraZeneca PLC Director/PDMR Shareholding
08 Marzo 2023 - 12:01PM
UK Regulatory (RNS & others)
TIDMAZN
RNS Number : 2133S
AstraZeneca PLC
08 March 2023
8 March 2023 11:01 GMT
Transactions by Persons Discharging Managerial
Responsibilities
AstraZeneca PLC (the Company) announced that, on 4 March 2023,
certain Persons Discharging Managerial Responsibilities of the
Company (PDMRs) were granted awards of the Company's ordinary
shares of $0.25 each (Ordinary Shares) under the terms of the
AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca
Performance Share Plan (AZPSP), as detailed in the table below.
PDMR Position Ordinary Ordinary Award price
Shares granted Shares granted per Ordinary
under the under the Share
AZDBP AZPSP
Executive Director
and Chief Executive
Pascal Soriot Officer 14,448 85,808 GBP108.21
---------------------- ---------------- ---------------- --------------
Executive Director
and Chief Financial
Aradhana Sarin Officer 7,403 38,046 GBP108.21
---------------------- ---------------- ---------------- --------------
The AZDBP award represents the portion of each PDMR's annual
bonus for 2022 that they are required to defer into shares. The
Ordinary Shares granted under the AZDBP are subject to a three-year
holding period and are due to vest on the third anniversary of
grant.
The AZPSP award is subject to a combination of performance
measures focused on scientific, commercial, financial and
sustainability performance. The performance measures will be
assessed over a three-year performance period (1 January 2023 to 31
December 2025). The Ordinary Shares granted under the AZPSP are
subject to a two-year holding period following the performance
period, and are due to vest on the fifth anniversary of grant.
Details of the performance measures attached to the AZPSP award
can be found in the Directors' Remuneration Report within the
AstraZeneca Annual Report and Form 20-F Information 2022, which is
available on the Company's website at
www.astrazeneca.com/annualreport202 2 .
Further details are set out in the attached notification, made
in accordance with the requirements of the EU Market Abuse
Regulation (as it forms part of UK law pursuant to the European
Union (Withdrawal) Act 2018).
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Pascal Soriot
---------------------------- -------------------------------------
Reason for the notification
2
-------------------------------------------------------------------
a) Position/status Chief Executive Officer
---------------------------- -------------------------------------
b) Initial notification Initial notification
/Amendment
---------------------------- -------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name AstraZeneca PLC
---------------------------- -------------------------------------
b) LEI PY6ZZQWO2IZFZC3IOL08
---------------------------- -------------------------------------
Details of the transaction(s): section to be repeated
4i for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description of the Ordinary Shares of US$0.25 each in
financial instrument, AstraZeneca PLC
type of instrument
Identification code GB0009895292
---------------------------- -------------------------------------
b) Nature of the transaction Grants of share awards under the
AstraZeneca Performance Share Plan
and the AstraZeneca Deferred Bonus
Plan
---------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
GBP108.21 100,256
----------
---------------------------- -------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
---------------------------- -------------------------------------
e) Date of the transaction 4 March 2023
---------------------------- -------------------------------------
f) Place of the transaction Outside a trading venue
---------------------------- -------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Aradhana Sarin
------------------------------- ------------------------------------
Reason for the notification
2
---------------------------------------------------------------------
a) Position/status Chief Financial Officer
------------------------------- ------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
---------------------------------------------------------------------
a) Name AstraZeneca PLC
------------------------------- ------------------------------------
b) LEI PY6ZZQWO2IZFZC3IOL08
------------------------------- ------------------------------------
Details of the transaction(s): section to be repeated
4i for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------
a) Description of the Ordinary Shares of US$0.25 each in
financial instrument, AstraZeneca PLC
type of instrument
Identification code GB0009895292
------------------------------- ------------------------------------
b) Nature of the transaction Grants of share awards under the
AstraZeneca Performance Share Plan
and the AstraZeneca Deferred Bonus
Plan
------------------------------- ------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
GBP108.21 45,449
----------
------------------------------- ------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
------------------------------- ------------------------------------
e) Date of the transaction 4 March 2023
------------------------------- ------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------- ------------------------------------
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on Twitter @AstraZeneca .
Contacts
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHUBSWROKUORAR
(END) Dow Jones Newswires
March 08, 2023 06:01 ET (11:01 GMT)
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mag 2023 a Giu 2023
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Giu 2022 a Giu 2023
